Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4059-4064

  Takeda, Yukihiro ^a   Kasai, Hisanori ^a   Uchida, Naomi ^a   Yoshida, Hiroshi ^a   Maekawa, Ryuji ^a   Sugita, Kenji ^a   Yoshioka, Takayuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

5 FU; Combination therapy; Nedaplatin; Osmotic pump; Squamous carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; NEDAPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

EID: 0032763551     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Totani T, Aono K, Komura M and Adachi Y: Synthesis of (glycolato-O, O′) diammineplatinum (II) and its related complexes. Chem Lett 3: 429-432, 1986.
2. Suzumura S, Kato T, Ueda R and Ohta K: Effect of treatment schedule on antitumor activity of glycolato-O, O′ diammineplatinum (II), a new platinum derivative: Comparison with cis-diammine-dichloroplatinum (II). Anticancer Res 9: 1083-1088, 1989.
3. Shiratori O, Kasai H, Uchida N, Takeda Y, Totani T and Sato K: Anti-tumor activity of 254-S, a platinum complex, in rodents. In: Recent advances in Chemotherapy Ishigami J., (ed), University of Tokyo Press, 635-636, 1985.
4. Koenuma M, Kasai H, Uchida N, Wada T, Hattori M, Oguma T, Totani T and Inaha M: Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammine glycolatoplatinum (254-S) and cis-diammine dichloroplatinum. Anticancer Res 15: 417-422, 1995.
5. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M and Gemba M: Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 52: 15-24, 1990.
6. Furuse K, Fukuoka M, Ohshima S, Ariyoshi Y, Fujii M, Kurita Y, Hasegawa K, Homma T, Tamura M, Inoue S, Nishiwaki Y, Kimura I and Niitani H: Phase II clinical study of (glycolato-O, O′) diammineplatinum (II), a new platinum complex, for primary lung cancer. Proc Am Soc Clin Oncol 8: 238, 1989.
7. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K and Saijo N: Phase II study of (glycolato-O, O′) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26: 393-396, 1990.
8. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ohta K: An early phase II study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19: 863-869, 1992.
9. Akaza H, Togashi M, Nishio Y Miki T, Kotake T, Matumura Y, Yoshida O and Aso Y: Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional -cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 31: 187-192, 1992.
10. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T and Ohta K: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother 19, 483-488, 1992.
11. Kato T, Noda K, Hirabayashi K and Nishimura H: Phase II study of cis-diammine (glycolato) platinum [254-S], a new platinum complex, for gynecological malignancy. Proc 16th Intl Cong Chemother, Anticancer section 823: 1-2, 1989.
12. Pratesi G, Gianni L, Manzotti C and Zuninno F: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloro-platinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 21: 237-240, 1988.
13. Kuroki M, Nakano S, Mitsugi K, Ichinose I, Anzai K, Nakamura M, Nagafuchi S and Niho Y: In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 29: 273-276, 1992.
14. Shirasaka T, Shimamoto Y, Ohshima H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32: 167-172, 1993.
15. Keane TE, Gingrich JR, Rosner G, Webb KS, Poulton SH and Walther PJ: Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of Cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res 54: 475-481, 1994.
16. Loehrer PJ, Einhorn LH, Williams SD, Huli SL, Estes NC and Pennington K: Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon Cancer Treat Rep 69: 1359-1363, 1985.
17. Decker DA, Drelichman A and Jacobs J: Adjuvant chemotherapy with cis-diamminedichloroplatinum 11 and 120-hour-infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of head and neck. Cancer 51: 1353-1355, 1983.
18. Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K and Yoshioka T: Sequence-dependent antitumor efficacy of combination chemotherapy of Nedaplatin, a novel platinum complex, with 5-fuluorouracil in an in vivo murine tumor model. Eur J Cancer 34: 1796-1801, 1998.
19. Uchida N, Kasai H, Takeda Y, Maekawa R, Sugita K and Yoshioka T: Synergy of the combination of Nedaplatin with Etoposide in murine and human lung carcinoma. Anticancer Res 18: 247-252, 1998.
20. Berenbaum MC: Criteria for analyzing interactions between biologically active agents. Adv in Cancer Res 35: 269-335, 1981.
21. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 47: 1-9, 1980.
22. Dunnett, CW: New tables for multiple comparisons with a control. Biometrics 20: 482-491, 1964.
23. Uchida N, Takeda Y, Kasai H, Maekawa R, Sugita K and Yoshioka T: Antitumor efficacy of Nedaplatin, a novel platinum complex, with Cyclophosphamide in murine and human tumor model. Anticancer Res 18: 3375-3379, 1998.
24. Inaba M, Mitsuhashi J and Ozawa S: Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 81: 1039-1044, 1990.
25. Yamada T, Tanase M, Watanabe A, Sawada H, Yamada Y, Shino Y, Yamashita J, Matsuda M and Nakano H: Evaluation of combination chemotherapy with 5-FU and CDDP for human gastric carcinoma transplanted into nude mice. Jpn J Cancer Chemother 24: 43-47, 1997.
26. Schmoll H-J: Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. Eur J Cancer 32A: S18-S22, 1996.
27. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 7: 425-432, 1989.
28. Scanlon KJ, Newman EM, Lu Y and Priest DG: Biochemical bases for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925, 1986.
29. Shirasaka T, Shimamoto Y, Ohshima H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32: 167-172, 1993.
30. Esaki T, Nakano S, Masumoto N, Fujishima H and Niho Y: Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1human squamous carcinoma cell line. Int J Cancer 65: 479-484, 1996
31. Ishikawa T and Ali-Osman F: Glutathione-associated cis-diammine-dichloro-platinum metabolism and ATP-dependent efflux from leukemia cell. J Biol Chem 268: 20116-20125, 1993.